Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa)
Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa). // Respiratory Medicine and Research. – URL: https://www.sciencedirect.com/science/article/pii/S2590041226000796?dgcid=rss_sd_all
Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa). Respiratory Medicine and Research. https://www.sciencedirect.com/science/article/pii/S2590041226000796?dgcid=rss_sd_all
“Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa).” Respiratory Medicine and Research.
@article{article64352,
title = {Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa)},
journal = {Respiratory Medicine and Research},
url = {https://www.sciencedirect.com/science/article/pii/S2590041226000796?dgcid=rss_sd_all}
}